Tariff Pressures Creep Into Dexcom’s Margin Outlook Despite Domestic Manufacturing Shield
Company Expects $20 Million Hit From Component Cost Inflation Passed Down By Suppliers.
Dexcom’s relatively strong position amid tariff-related uncertainty is rooted in its long-standing investments in domestic manufacturing, but raw material inflation is driving cost concerns even in the face of operational efficiencies.
